Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [52]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Intestinal Epithelial Cell Surface Membrane Glycoprotein Synthesis
Weiser, M. M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44141-0 · Cited by 1,098
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936
Self-citationLost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Research works printed but not linked: 9
- Mariadason, 1997, Am. J. Physiol., 272, G705
- Heerdt, 1994, Cancer Res., 54, 3288
- Mei, 2004, Int. J. Oncol., 25, 1509
- Fischle, 2001, Biochem. Cell Biol., 79, 337, 10.1139/o01-116 · DOI · Paper page
- Mariadason, 2001, Cancer Res., 61, 3465
- Sowa, 1999, Cancer Res., 59, 4266
- Mariadason, 2003, Cancer Res., 63, 8791
- Yang, 2001, Cancer Res., 61, 565
- Bailey, 1999, Mol. Endocrinol., 13, 1155, 10.1210/mend.13.7.0305 · doi:10.1210/mend.13.7.0305 · Paper page
Cited by
Items 101–200 of 611
Histone deacetylase inhibitors selectively suppress expression of HDAC7
Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R. B., & Marks, P. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0251 · Cited by 100
“increased in human tumor samples of colon cancer compared with normal tissue (18, 20).”
BackgroundLi, Q., Ding, C., Meng, T., Lu, W., Liu, W., Hao, H., & Cao, L. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.11.004 · Cited by 104
Ueki, N., Lee, S., Sampson, N. S., & Hayman, M. J. (2013) · Nature Communications · doi:10.1038/ncomms3735 · Cited by 105
The role of signal transducers and activators of transcription in colon cancer
Klampfer, L. (2008) · Frontiers in Bioscience · doi:10.2741/2893 · Cited by 96
“Finally, HDAC1, HDAC2 and HDAC3 have also been shown to be upregulated in a variety of human cancers, including colon cancer (9, 45).”
BackgroundAutophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
Rikiishi, H. (2011) · BioMed Research International · doi:10.1155/2011/830260 · Cited by 94
“Recently, silencing of HDAC3 has been found to induce the expression of p21 and cell cycle arrest in the G2/M phase in colon cancer cells [42].”
BackgroundHDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition
Ji, H., Zhou, Y., Zhuang, X., Zhu, Y., Wu, Z., Lu, Y., Li, S., Zeng, Y., Lu, Q. R., Huo, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3767 · Cited by 100
“Increased HDAC levels are widely observed in diverse cancers and might contribute to the inactivation of tumor suppressor genes, and thus, these increasedHDAC levels are potential targets for tumor therapy (24, 37, 38).”
BackgroundWang, H., Yu, N., Chen, D., Lee, K. C. L., Lye, P. L., Chang, J. W. W., Deng, W., Ng, M. C. Y., Lu, T., Khoo, M. L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2003552 · Cited by 93
Jeong, Y., Du, R., Zhu, X., Yin, S., Wang, J., Cui, H., Cao, W., & Lowenstein, C. J. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1013565 · Cited by 101
“For example, HDAC2 expression is increased in HDAC1-deficient cells, such as mouse embryonic stem cells, fibroblasts, T cells, and various human cancer cells, [48–51].”
BackgroundIshii, S., Kurasawa, Y., Wong, J., & Yu-Lee, L.-Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710140105 · Cited by 92
“Both overexpression and depletion of HDAC3 lead to the accumulation of cells in G2/M phase (16, 17).”
BackgroundGloghini, A., Buglio, D., Khaskhely, N. M., Georgakis, G. V., Orlowski, R. Z., Neelapu, S. S., Carbone, A., & Younes, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07887.x · Cited by 105
“…Publishing Ltd, British Journal of Haematology, 147, 515–525 519 neoplastic breast tissues for HDAC6, and leiomyosarcoma for HDAC8(Waltregny et al, 2004; Zhang et al, 2004; Wilson et al, 2006; Ishihama et al, 2007; Nakagawa et al, 2007; Park et al, 2007; Kaler et al, 2008; Spurling et al, 2008).”
BackgroundXiong, S. D., Yu, K., Liu, X. H., Yin, L., Kirschenbaum, A. M., Yao, S., Narla, G., DiFeo, A. V., Wu, J. B., Yuan, Y., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24325 · Cited by 101
Gurard-Levin, Z. A., Kilian, K. A., Kim, J., Bähr, K., & Mrksich, M. (2010) · ACS Chemical Biology · doi:10.1021/cb100088g · Cited by 89
Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
Kotian, S., Liyanarachchi, S., Zelent, A., & Parvin, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.194233 · Cited by 88
Godman, C. A., Joshi, R., Tierney, B. R., Greenspan, E., Rasmussen, T. P., Wang, H.-W., Shin, D.-G., Rosenberg, D. W., & Giardina, C. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.10.6561 · Cited by 87
Wang, L., Xiang, S., Williams, K. A., Dong, H., Bai, W., Nicosia, S. V., Khochbin, S., Bepler, G., & Zhang, X. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044265 · Cited by 90
“For example, overexpression of HDAC1, HDAC2, HDAC3, and HDAC6 has been observed in colon, breast, prostate, cervical and gastric cancers [21–28].”
BackgroundZhang, Y., Feng, J., Jia, Y., Wang, X., Zhang, L. J., Liu, C., Fang, H., & Xu, W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101605z · Cited by 86
Chiu, H., Yeh, Y.-L., Wang, Y., Huang, W., Chen, Y., Chiou, Y., Ho, S., Lin, P., & Wang, Y.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076340 · Cited by 90
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Manzotti, G., Ciarrocchi, A., & Sancisi, V. (2019) · Cancers · doi:10.3390/cancers11030304 · Cited by 91
Lehmann, A., Denkert, C., Budczies, J., Buckendahl, A., Darb‐Esfahani, S., Noske, A., Müller, B. M., Bahra, M., Neuhaus, P., Dietel, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-395 · Cited by 91
“Although there is strong evidence that aberrant HDAC activity can contribute to the development of cancer, reports on isoform specific expression patterns of HDACs in tumor tissue are sparse [23,24].”
BackgroundZeng, L.-S., Yang, X.-Z., Wen, Y.-F., Mai, S.-J., Wang, M.-H., Zhang, M.-Y., Zheng, X. F. S., & Wang, H.-Y. (2016) · Aging · doi:10.18632/aging.100980 · Cited by 82
Histone Deacetylase HDAC4 Promotes Gastric Cancer SGC-7901 Cells Progression via p21 Repression
Kang, Z., Wang, C., Zhang, W., Zhang, J., Yuan, C., Zhao, P., Lin, Y., Hong, S., Li, C., & Wang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098894 · Cited by 82
“The proproliferative effect of HDAC4 in gastric cancer cells is consistent with that reported previously for the class I HDACs, HDAC1, -2, and -3 [16].”
BackgroundMandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08124.x · Cited by 81
“Moreover, siRNA mediated knockdown of specific HDACs in tumour cells has been shown to inhibit cell growth and survival (Glaser et al, 2003; Zhu et al, 2004; Bolden et al, 2006; Wilson et al, 2006).”
BackgroundNuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Wong, M., Guo, C. H., & Zhang, J. (2014) · PubMed Central · Cited by 104
Sodeifian, G., Ardestani, N. S., Sajadian, S. A., Golmohammadi, M. R., & Fazlali, A. (2020) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.9b01069 · Cited by 83
Moseley, V. R., Morris, J., Knackstedt, R. W., & Wargovich, M. J. (2013) · PubMed · Cited by 79
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues
Jin, K. L., Pak, J. H., Park, J., Choi, W., Lee, J., Kim, J.-H., & Nam, J. (2008) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2008.19.3.185 · Cited by 79
“Silencing of HDAC3 expression in colon cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis, similar effects were observed for HDAC1 and HDAC2.”
BackgroundResultInfluentialYe, Y., Jin, L., Wilmott, J. S., Hu, W. L., Yosufi, B., Thorne, R. F., Liu, T., Rizos, H., Yan, X. G., Dong, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms2489 · Cited by 78
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer
Poyet, C., Jentsch, B., Hermanns, T., Schweckendiek, D., Seifert, H., Schmidtpeter, M., Sulser, T., Moch, H., Wild, P. J., & Kristiansen, G. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-10 · Cited by 87
“Class I HDACs are divided into four isoforms (HDAC-1, −2, −3 and −8) and are known to be associated with an overexpression in different types of cancer such as colon and prostate cancer [7,8].”
BackgroundComplex neuroprotective and neurotoxic effects of histone deacetylases
Thomas, E. A., & D'Mello, S. R. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14309 · Cited by 74
Li, X., Inks, E. S., Li, X., Hou, J., Chou, C. J., Zhang, J., Jiang, Y., Zhang, Y., & Xu, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401877m · Cited by 76
Osipovich, A. B., Gangula, R., Vianna, P. G., & Magnuson, M. A. (2016) · Development · doi:10.1242/dev.141465 · Cited by 76
“HDAC3 is known to be involved in the control of cell cycle progression and, similar to the defects that we observed in Setd5 null mESCs, depletion of HDAC3 decreases the number of cells in S phase and leads to an accumulation of cells in G2/M phase (Bhaskara et al., 2008; Wilson et al., 2006).”
BackgroundAdhikari, N., Amin, S. A., Trivedi, P., Jha, T., & Ghosh, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.081 · Cited by 74
Targeting of HDAC8 and investigational inhibitors in neuroblastoma
Oehme, I., Deubzer, H. E., Lodrini, M., Milde, T., & Witt, O. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241658 · Cited by 75
“HDAC3 was the third mammalian deacetylase to be identified [61-63].”
BackgroundInfluentialYang, H., Salz, T., Zajac‐Kaye, M., Liao, D., Huang, S., & Qiu, Y. (2014) · The FASEB Journal · doi:10.1096/fj.14-250654 · Cited by 84
Snykers, S., Henkens, T., De Rop, E., Vinken, M., Fraczek, J., De Kock, J., De Prins, E., Geerts, A., Rogiers, V., & Vanhaecke, T. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.009 · Cited by 74
“HDAC-1 in prostate, gastric and colon tumors, HDAC-2 in colorectal, cervical and gastric cancer [26], and HDAC-3 in colon cancer [38].”
BackgroundFatty acids as potential adjunctive colorectal chemotherapeutic agents
Fauser, J. K., Prisciandaro, L. D., Cummins, A. G., & Howarth, G. S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.8.15281 · Cited by 70
Jiang, Y., & Hsieh, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411939111 · Cited by 71
“In human colon cancer cells, HDAC3 levels are elevated, which have been suggested to control cells in both S and gap 2/mitosis (G2/M) phase (12).”
BackgroundEpigenomic regulation of host–microbiota interactions
Alenghat, T., & Artis, D. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.007 · Cited by 70
The potential role of epigenetic therapy in multiple myeloma
Smith, E. M. K., Boyd, K. D., & Davies, F. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07976.x · Cited by 77
“…cancers, shown firstly by the correlation with expression (for example in prostate (Halkidou et al, 2004), breast (Zhang et al, 2004), colorectal (Wilson et al, 2006, 2008; Spurling et al, 2008), stomach (Choi et al, 2001; Song et al, 2005), lung (Sasaki et al, 2004), and esophagial (Toh et al,…”
BackgroundRajendran, P., Dashwood, W.-M., Li, L., Kang, Y., Kim, E., Johnson, G., Fischer, K. A., Löhr, C. V., Williams, D. E., Ho, E., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0132-y · Cited by 70
“The corroboration of HDAC3 as a target of SFN in vivo is important considering the critical role of this HDAC in regulating colon cancer growth and tumorigenesis [3].”
BackgroundJeong, M., Ko, H., Jeon, H., Sung, G., Park, S., Jun, W. J., Lee, Y.-H., Lee, J., Lee, S.-W., Yoon, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10790 · Cited by 72
“HDACs are transcriptional co-repressors that regulate cell cycle arrest, cell differentiation, and apoptosis in cancer cell lines [34].”
BackgroundRecent Trends in In Situ Enzyme-Activatable Prodrugs for Targeted Cancer Therapy
Sun, I., Yoon, H. Y., Lim, D., & Kim, K. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00082 · Cited by 69
Dong, Z., Tan, R., Cao, J. P., Yang, Y., Kong, C., Du, J., Zhu, S., Zhang, Y., Lü, J., Huang, B., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.036 · Cited by 69
Dhar, S. S., Alam, H., Li, N., Wagner, K. W., Chung, J., Ahn, Y. W., & Lee, M. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521625 · Cited by 71
“In agreement with these reports, it has been shown that HDAC3 appeared to be up-regulated and to repress the tumor suppressor gene p21 in colorectal cancer cells (47).”
ResultStiborová, M., Eckschlager, T., Poljaková, J., Hraběta, J., Adam, V., Kizek, R., & Frei, E. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802884286 · Cited by 76
Anticancer properties of chimeric HDAC and kinase inhibitors
Biersack, B., Polat, S., & Höpfner, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.005 · Cited by 77
Kai, M., Kanaya, N., Wu, S. V., Mendez‐Dorantes, C., Nguyen, D. M., Luu, T. H., & Chen, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3376-5 · Cited by 70
“[62, 63]; p21 promotes cell cycle arrest in response to stimuli, including salinomycin [64, 65]; and HDAC inhibitors have been shown to induce acetylation of histones H3 and H4, which leads to activation of p21 and cell cycle regulation [37].”
Escaffit, F., Vaute, O., Chevillard-Briet, M., Segui, B., Takami, Y., Nakayama, T., & Trouche, D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00869-06 · Cited by 67
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
“The cell cycle inhibition caused by SAHA was accompanied by an increase of the cyclin-CDK inhibitor p21 that was previously shown to be a consequence of histone hyperacetylation induced by broad-spectrum inhibitors targeting largely HDAC Class I (Richon et al, 2000; Wilson et al, 2006; Figure 3E).”
BackgroundKato, T., Shimono, Y., Hasegawa, M., Jijiwa, M., Enomoto, A., Asai, N., Murakumo, Y., & Takahashi, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4368 · Cited by 73
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3
Pasricha, S.-R., Lim, P. J., Duarte, T. L., Casu, C., Oosterhuis, D., Mleczko-Sanecka, K., Suciu, M., Da Silva, A. R., Al-Hourani, K., Arezes, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00500-z · Cited by 65
Han, A., Bennett, N. E., Bettaieb, A., Whelan, J. N., & Donohoe, D. R. (2018) · Oncotarget · doi:10.18632/oncotarget.25546 · Cited by 76
“In colorectal cancer, HDAC 1, HDAC 2, and HDAC 3 are highly expressed in order to accelerate cell proliferation, growth and survival [42, 43].”
BackgroundMCM-2 is a therapeutic target of Trichostatin A in colon cancer cells
Liu, Y., He, G., Wang, Y., Guan, X., Pang, X., & Zhang, B. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.05.643 · Cited by 65
Histone deacetylase 3 is required for centromeric H3K4 deacetylation and sister chromatid cohesionPreprint
Éot-Houllier, G., Fulcrand, G., Watanabe, Y., Magnaghi-Jaulin, L., & Jaulin, C. (2008) · Genes & Development · doi:10.1101/gad.484108 · Cited by 81
“SAC inhibition due to Mad2 depletion abolished the HDAC3-1-dependent increase in mitotic index, indicating that HDAC3 knockdown activates the SAC, consistent with previous observations that cells in which HDAC3 is depleted are blocked in the G2/M phase (Li et al. 2006; Wilson et al. 2006) and in mitosis in a SAC-depen…”
Trivedi, P., Adhikari, N., Amin, S. A., Jha, T., & Ghosh, B. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.030 · Cited by 62
“, 2013), colon cancer (Wilson et al., 2006), leukemia (Zhang et al.”
BackgroundKerl, K., Ries, D., Unland, R., Borchert, C., Moreno, N., Hasselblatt, M., Jürgens, H., Kool, M., Görlich, D., Eveslage, M., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-286 · Cited by 67
“First, several HDACs (including HDAC 1, 2, 5, 6, 9 and SIRT1) are, like in many other tumor entities [1,2], overexpressed in rhabdoid tumors.”
BackgroundStrobl, J. S., Cassell, M., Mitchell, S. M., Reilly, C. M., & Lindsay, D. S. (2007) · Journal of Parasitology · doi:10.1645/ge-1043r.1 · Cited by 70
Dávalos-Salas, M., Montgomery, M. K., Reehorst, C. M., Nightingale, R., Ng, I., Anderton, H., Al-Obaidi, S., Lesmana, A., Scott, C. M., Ioannidis, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13180-8 · Cited by 62
Self-citationFakih, M., Pendyala, L., Fetterly, G. J., Toth, K., Zwiebel, J. A., Espinoza‐Delgado, I., Litwin, A. M., Rustum, Y. M., Ross, M. E., Holleran, J. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2999 · Cited by 65
Targeting the epigenome for treatment of cancer
Geutjes, E.-J., Bajpe, P. K., & Bernards, R. (2011) · Oncogene · doi:10.1038/onc.2011.552 · Cited by 71
“Lysine deacetylases HDAC1 Deacetylates histones and non-histone proteins Prostate, gastric, colon and breast cancers Overexpression (Choi et al., 2001; Halkidou et al., 2004; Zhang et al., 2005; Wilson et al., 2006; Weichert et al., 2008a) HDAC2 Deacetylates histones and non-histone proteins Colorectal, cervical and g…”
BackgroundHistone deacetylase inhibitors in cancer therapy. A review
Hraběta, J., Stiborová, M., Adam, V., Kizek, R., & Eckschlager, T. (2013) · Biomedical Papers · doi:10.5507/bp.2013.085 · Cited by 74
Deacetylase inhibitors - focus on non-histone targets and effects
Ocker, M. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i5.55 · Cited by 66
Seidel, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.026 · Cited by 61
Zhang, Y., Feng, J., Liu, C., Zhang, L., Jiao, J., Fang, H., Su, L., Zhang, X., Zhang, J., Li, M., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.060 · Cited by 60
More than two decades of Apc modeling in rodents
Zeineldin, M., & Neufeld, K. L. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.01.001 · Cited by 66
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
Matthews, G. M., Mehdipour, P., Cluse, L. A., Falkenberg, K. J., Wang, E., Roth, M., Santoro, F., Vidacs, E., Stanley, K., House, C. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632984 · Cited by 59
“Knockdown of HDAC3, and to a lesser extent HDAC1 and 2, resulted in growth inhibition in human colon cancer cell lines; however, the biological response was less potent than vorinostat treatment.(25) Depletion or pharmacological inhibition of HDAC3 triggered apoptosis in cutaneous T-cell lymphoma and multiple myeloma.”
Zhang, Y., Liu, Y., Duan, J., Yan, H., Zhang, J., Zhang, H., Fan, Q., Luo, F., Yan, G., Qiao, K., et al. (2015) · Hepatology · doi:10.1002/hep.28395 · Cited by 61
An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1
Hanigan, C. L., van Engeland, M., de Bruïne, A. P., Wouters, K. A., Weijenberg, M. P., Eshleman, J. R., & Herman, J. G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.078 · Cited by 65
Epigenetic changes in colorectal cancer
Jia, Y., & Guo, M. (2011) · 癌症:英文版 · doi:10.5732/cjc.011.10245 · Cited by 66
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Foley, C., & Mitsiades, N. (2016) · Hormones and Cancer · doi:10.1007/s12672-015-0239-9 · Cited by 65
“The dysregulation of class I KDACs has been implicated in cancer, as they have been established to play key roles in the regulation of cell cycle [155, 156].”
Advances of Epigenetic Biomarkers and Epigenome Editing for Early Diagnosis in Breast Cancer
Sarvari, P., Sarvari, P., Ramírez‐Díaz, I., Mahjoubi, F., & Rubio, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179521 · Cited by 74
Paik, P. K., & Krug, L. M. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c5e366 · Cited by 64
Review of short-chain fatty acids effects on the immune system and cancer
Fattahi, Y., Heidari, H. R., & Khosroushahi, A. Y. (2020) · Food Bioscience · doi:10.1016/j.fbio.2020.100793 · Cited by 64
Intestinal Cell Proliferation and Senescence Are Regulated by Receptor Guanylyl Cyclase C and p21
Basu, N., Saha, S., Khan, I., Ramachandra, S. G., & Visweswariah, S. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511311 · Cited by 60
“HDAC3 is overexpressed in approximately half of all colorectal carcinomas, resulting in repression of p21 expression and enhanced cell proliferation (39, 40).”
BackgroundWang, H., Liu, Y.-C., Zhu, C.-Y., Yan, F., Wang, M.-Z., Chen, X., Wang, X.-K., Pang, B., Li, Y.-H., Liu, D.-H., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01792-8 · Cited by 62
Proteomic changes during intestinal cell maturation in vivo
Chang, J., Chance, M. R., Nicholas, C., Ahmed, N., Guilmeau, S., Flández, M., Wang, D., Byun, D.-S., Nasser, S., Albanese, J. M., et al. (2008) · Journal of Proteomics · doi:10.1016/j.jprot.2008.08.003 · Cited by 58
Self-citationHwang, J., Lee, J. A., & Pallas, D. C. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.739920 · Cited by 56
Modulation of cell cycle regulators by HDACs
Seto, E. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s303 · Cited by 69
“HDAC3 expression is restricted to the proliferative compartment of the mouse small intestine and colon and regulates proliferation by repressing p21 expression (66).”
BackgroundAdvancements in the field of intravaginal siRNA delivery
Yang, S., Chen, Y. A., Ahmadie, R., & Ho, E. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.023 · Cited by 62
“Furthermore, the promising potential of siRNA-based therapy for the treatment of other cancers such as those of the melanoma [23–25], lung [26,27], liver [28], and colon [29,30] have also been shown.”
BackgroundCRISPR/Cas mediated epigenome editing for cancer therapy
Ansari, I., Chaturvedi, A., Chitkara, D., & Singh, S. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.018 · Cited by 62
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
Chüeh, A. C., Tse, J. W. T., Dickinson, M. J., Ioannidis, P., Jenkins, L. J., Tögel, L., Tan, B., Luk, I. Y., Dávalos-Salas, M., Nightingale, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0466 · Cited by 57
Self-citationBacklund, M. G., Mann, J. R., Holla, V. R., Shi, Q., Daikoku, T., Dey, S. K., & DuBois, R. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2893 · Cited by 60
“November 15, 2008 elevated in tumor samples (25, 28, 29 ).”
Pulya, S., Patel, T. K., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114470 · Cited by 56
Histone modifications as a pathogenic mechanism of colorectal tumorigenesis
Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53
Epigenetics, stem cells and epithelial cell fate
Vincent, A., & SEUNINGEN, I. V. (2009) · Differentiation · doi:10.1016/j.diff.2009.07.002 · Cited by 58
“DNA methylation occurs on CpG dinucleotides, is mediated by DNA methyltransferases (DNMTs) and follows a cell-specific profile that is established during development and maintained through cell divisions (Wilson et al., 2006).”
BackgroundInfluentialGanai, S. A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.130 · Cited by 53
Xiao, T., Wu, S., Yan, C., Zhao, C., Jin, H., Yan, N., Xu, J., Wu, Y., Li, C., Shao, Q., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9201 · Cited by 65
“This butyrate-mediated growth inhibition in colon cancer cells is associated with the direct silencing of HDAC3 expression, the repression of Cyclin B or the upregulation of cyclin-dependent kinase inhibitor 1 (43,44).”
Wang, T., Chern, E., Hsu, C., Tseng, K.-C., & Chao, H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3188 · Cited by 54
Wilson, A. J., Holson, E. B., Wagner, F. F., Zhang, Y.-L., Fass, D. M., Haggarty, S. J., Bhaskara, S., Hiebert, S. W., Schreiber, S. L., & Khabele, D. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.6.15956 · Cited by 58
Self-citationQuinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Dhuguru, J., & Ghoneim, O. (2022) · Molecules · doi:10.3390/molecules27072294 · Cited by 58
Kumar, N., Tomar, R., Pandey, A. K., Tomar, V., Singh, V. K., & Chandra, R. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1369423 · Cited by 52
USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3
Zhan, W., Liao, X., Liu, J., Tian, T., Yu, L., & Li, R. (2020) · Oncogenesis · doi:10.1038/s41389-020-0234-z · Cited by 51
Kang, K. A., Piao, M. J., Kim, K. C., Zheng, J., Yao, C. W., CHA, J. W., Kim, H. S., Kim, D. H., Bae, S. C., & Hyun, J. W. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2129 · Cited by 51
Wang, D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788085287 · Cited by 53
Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer
Marcotullio, L. D., Canettieri, G., Infante, P., Greco, A., & Gulino, A. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.01.002 · Cited by 55
Negmeldin, A. T., Knoff, J. R., & Pflum, M. K. H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.076 · Cited by 51
“For example, HDAC1 was overexpressed in lung [8], breast [9], and colon cancers [10].”
BackgroundHistone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Budillon, A., Gennaro, E. D., Bruzzese, F., Rocco, M., Manzo, G., & Caraglia, M. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832450 · Cited by 55
Recent advances in histone deacetylase targeted cancer therapy
Hoshino, I., & Matsubara, H. (2010) · Surgery Today · doi:10.1007/s00595-010-4300-6 · Cited by 53
Yu, J. I., Choi, C., Shin, S.-W., Son, A.-R., Lee, G.-H., Kim, S., & Park, H. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-15165-3 · Cited by 49
Total Synthesis and Biological Evaluation of Grassypeptolide A
Liu, H., Liu, Y., Wang, Z., Xing, X., Maguire, A. R., Luesch, H., Zhang, H., Xu, Z., & Ye, T. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201203667 · Cited by 48
Metadata
- Authors
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Kyoto Prefectural University of Medicine (JP)
- Vall d'Hebron Institut de Recerca (ES)
- Corresponding author
- Mariadason, John M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 19
- Pages
- 13548-13558
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105095164
- Semantic Scholar
- c2db47db00c10ecf03aae7c6c6f1c3b194c81502
- Cited by
- 575
- References
- 43
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 31 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 30 · 2016: 30 · 2015: 38 · 2014: 32 · 2013: 40 · 2012: 28
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5273 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088104, R01CA100823, CA88104-04, CA100823-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, class I HDACs, colon cancer, histone deacetylase inhibitors, apoptosis, alkaline phosphatase, duodenal adenoma, crypt cells, gene silencing, tumor suppressor
- MeSH terms
- Cell Differentiation, Colon, Colonic Neoplasms, Histone Deacetylases, Humans, Time Factors, Down-Regulation, Up-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, Caco-2 Cells, Gene Silencing, HCT116 Cells, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.